[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621440":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":10,"centralContacts":32,"locations":40,"responsibleParty":146,"collaborators":148,"id":152,"slug":153,"hasResults":154,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":154,"sex":160,"minAge":161,"maxAge":10,"enrollmentInfo":162,"targetDuration":165,"studyType":166,"phases":10,"briefSummary":167,"conditions":168,"keywords":173,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":195},{"fullName":5,"class":6},"Pomeranian Medical University Szczecin","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"HIV-1 subtype A6",null,"This cohort includes adults living with HIV-1 with a confirmed subtype A6 infection who received at least one dose of long-acting injectable cabotegravir plus rilpivirine (CAB\u002FRPV LA) as part of routine clinical care. Participants are treatment-experienced and include individuals with suppressed or unsuppressed viral load at treatment initiation. Clinical outcomes, including virologic effectiveness, treatment persistence, adherence, and discontinuation, are assessed retrospectively using existing medical records. This cohort is matched with the subtype B cohort using propensity score methods.",[13],"Drug: Cabotegravir Plus Rilpivirine Long-Acting Injectable",{"label":15,"type":10,"description":16,"interventionNames":17},"HIV-1 Subtype B Cohort","This cohort consists of adults living with HIV-1 with a confirmed subtype B infection who received long-acting injectable cabotegravir plus rilpivirine (CAB\u002FRPV LA) in routine clinical practice. Participants are selected and matched to the subtype A6 cohort based on predefined confounding variables, including age, gender, body mass index category, and CD4 cell nadir. Outcomes are evaluated retrospectively to provide a comparative real-world context for the subtype A6 cohort.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"HIV-1 Subtype Unknown Cohort","This cohort includes adults living with HIV-1 who received long-acting injectable cabotegravir plus rilpivirine (CAB\u002FRPV LA) and had no documented HIV-1 subtype at the time of treatment initiation. Participants are analyzed as an unmatched descriptive group. Retrospective clinical outcome data are collected from medical records. For selected participants, proviral DNA genotyping from blood samples is performed after initial analyses to explore the clinical relevance of HIV-1 subtype knowledge prior to switching to long-acting injectable therapy.",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Cabotegravir Plus Rilpivirine Long-Acting Injectable","Cabotegravir plus rilpivirine long-acting (CAB\u002FRPV LA) is a complete antiretroviral regimen administered as intramuscular injections and approved for the maintenance treatment of HIV-1 infection in adults. In this observational, retrospective study, CAB\u002FRPV LA is used as part of routine clinical care and is not assigned by the study protocol. Participants received CAB\u002FRPV LA according to local prescribing information, including dosing intervals and injection windows.\n\nThe study evaluates real-world clinical outcomes of CAB\u002FRPV LA across different HIV-1 subtype groups (subtype A6, subtype B, and unknown subtype). Outcomes of interest include virologic effectiveness, treatment persistence, adherence to injection schedules, and treatment discontinuation. No study-specific modifications to dosing, administration, or clinical management are performed.",[15,19,9],[29,30,31],"CAB\u002FRPV LA","Long-Acting Cabotegravir and Rilpivirine","Cabotegravir + Rilpivirine",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"Miłosz Parczewski, prof. dr hab. n. med.","CONTACT","+48 91 813 94 41","klinzak@pum.edu.pl",{"name":39,"role":35,"phone":10,"phoneExt":10,"email":10},"Karolina Sorbian-Gajewska",[41,60,76,91,104,117,131],{"facility":42,"status":43,"city":44,"state":10,"zip":10,"country":45,"countryCode":10,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Hospital Na Bulovce Praque HIV Centre, Department of Infectious Diseases","RECRUITING","Prague","Czechia",{"type":47,"coordinates":48},"Point",[49,50],14.42076,50.08804,{"lat":50,"lon":49},[53,57],{"name":54,"role":35,"phone":55,"phoneExt":10,"email":56},"David Jilich","+420 26608 2629","hiv@bulovka.cz",{"name":58,"role":59,"phone":10,"phoneExt":10,"email":10},"David Jilich, MD","PRINCIPAL_INVESTIGATOR",{"facility":61,"status":43,"city":62,"state":10,"zip":10,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"MainFachArzt","Frankfurt","Germany","DE",{"type":47,"coordinates":66},[67,68],10.53333,49.68333,{"lat":68,"lon":67},[71,75],{"name":72,"role":35,"phone":73,"phoneExt":10,"email":74},"Pavel Khaykin, MD","+49 69 253103","praxis@mainfacharzt.de",{"name":72,"role":59,"phone":10,"phoneExt":10,"email":10},{"facility":77,"status":78,"city":79,"state":80,"zip":81,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Katedra Chorób Zakaźnych i Niedoborów Immunologicznych","NOT_YET_RECRUITING","Szczecin","West Pomeranian Voivodeship","71-455","Poland","PL",{"type":47,"coordinates":85},[86,87],14.55302,53.42894,{"lat":87,"lon":86},[90],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},{"facility":92,"status":43,"city":93,"state":10,"zip":10,"country":82,"countryCode":83,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Wojewódzki Szpital Obserwacyjno-Zakaźny","Bydgoszcz",{"type":47,"coordinates":95},[96,97],18.00762,53.1235,{"lat":97,"lon":96},[100,103],{"name":101,"role":35,"phone":10,"phoneExt":10,"email":102},"Anita Olczak, dr hab. n. med.","sekretariat@wsoz.pl",{"name":101,"role":59,"phone":10,"phoneExt":10,"email":10},{"facility":105,"status":43,"city":106,"state":10,"zip":10,"country":82,"countryCode":83,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"Szpitale Pomorskie","Gdansk",{"type":47,"coordinates":108},[109,110],18.64912,54.35227,{"lat":110,"lon":109},[113,115],{"name":114,"role":35,"phone":10,"phoneExt":10,"email":10},"Maria Hlebowicz, Dr n.med.",{"name":116,"role":59,"phone":10,"phoneExt":10,"email":10},"Maria Hlebowicz, dr n. med.",{"facility":118,"status":43,"city":119,"state":10,"zip":10,"country":82,"countryCode":83,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Wojewódzki Szpital Zakaźny w Warszawie","Warsaw",{"type":47,"coordinates":121},[122,123],21.01178,52.22977,{"lat":123,"lon":122},[126,130],{"name":127,"role":35,"phone":128,"phoneExt":10,"email":129},"Iwona Cielniak, dr n. med.","22 335 53 51","sekretariat@zakazny.pl",{"name":127,"role":59,"phone":10,"phoneExt":10,"email":10},{"facility":132,"status":43,"city":133,"state":10,"zip":10,"country":82,"countryCode":83,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"Wrocławskie Centrum Zdrowia","Wroclaw",{"type":47,"coordinates":135},[136,137],17.03006,51.10286,{"lat":137,"lon":136},[140,144],{"name":141,"role":35,"phone":142,"phoneExt":10,"email":143},"Aleksandra Szymczyk, dr n. med.","71 326 67 30","metadon@spzoz.wroc.pl",{"name":145,"role":59,"phone":10,"phoneExt":10,"email":10},"Aleksandra Szymczak, dr n. med.",{"type":147,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[149],{"name":150,"class":151},"ViiV Healthcare","INDUSTRY","100621440","long-acting-cabotegravir-and-rilpivirine-in-people-living-with-hiv-1-subtype-a6-a-real-world-retrospective-study-100621440",false,"NCT07370649","Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study","Long-Acting Cabotegravir And Rilipivirine In People Living With HIV-1 Subtype A6. A Multicentre Real-world, Retrospective Matched Case Study","LACRIS","Inclusion Criteria:\n\n* Confirmed diagnosis of HIV-1 infection\n* Age ≥18 years at the time of initiation of long-acting cabotegravir plus rilpivirine (CAB\u002FRPV LA)\n* Received at least one dose of CAB\u002FRPV LA as part of routine clinical care\n* Availability of relevant clinical data in medical records for retrospective analysis\n* Signed informed consent for use of clinical data\n* Agreement to provide an additional blood sample for proviral DNA genotyping, if HIV-1 subtype was unknown at treatment initiation\n\nExclusion Criteria:\n\n\\- Lack of patient consent for use of clinical data for research purposes","ALL","18 Years",{"count":163,"type":164},250,"ESTIMATED","24 Months","OBSERVATIONAL","This study evaluates the real-world effectiveness and safety of a long-acting injectable HIV treatment consisting of cabotegravir and rilpivirine in people living with HIV-1. The focus is on individuals with HIV-1 subtype A6, which is common in Eastern Europe and among people who acquired HIV in that region, and on comparison with individuals with subtype B and those with an unknown subtype.\n\nAlthough long-acting cabotegravir and rilpivirine are widely used and effective, limited real-world data are available on how well this treatment works in people with HIV-1 subtype A6. This is important because subtype A6 has been suggested as a potential risk factor for treatment failure, but current evidence is inconclusive.\n\nThe study uses existing medical records from treatment centers in Poland, Germany, and the Czech Republic. It includes adults with HIV who have received at least one injection of long-acting cabotegravir and rilpivirine and follows their clinical outcomes for up to 24 months. Researchers will assess viral suppression, treatment persistence, adherence to injection schedules, and reasons for treatment discontinuation.\n\nThe results of this study will help clinicians better understand whether HIV-1 subtype A6 affects treatment outcomes and whether knowing a patient's HIV subtype is important when deciding to switch to long-acting injectable therapy. The findings may support safer and more effective use of this treatment in diverse patient populations.",[169,170,171,172],"Human Immunodeficiency Virus (HIV)-1 Infection","HIV-1 Subtype A6 Infection","HIV-1 Subtype B Infection","Virologically Suppressed HIV-1 Infection Receiving Long-Acting Antiretroviral Therapy",[174,175,176,177,29,178,179,180,181,182,183,184,185],"HIV-1","Long-Acting Antiretroviral Therapy","Cabotegravir","Rilpivirine","HIV-1 Subtype A6","HIV-1 Subtype B","Virologic Suppression","Real-World Study","Retrospective Study","Injectable HIV Therapy","Treatment Persistence","Virologic Failure","2026-06-09",{"date":188,"type":189},"2026-06-11","ACTUAL",{"date":191,"type":189},"2026-05-12",{"date":193,"type":164},"2027-03",{"name":5,"class":6},7]